retatrutide weight loss trial Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 weeks in all doses in the Retatrutide FDA Approval Status 2026:
Pay in 4 interest-free payments of $7.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
















:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)










